<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212587</url>
  </required_header>
  <id_info>
    <org_study_id>TIPBCC002</org_study_id>
    <secondary_id>165476</secondary_id>
    <nct_id>NCT02212587</nct_id>
  </id_info>
  <brief_title>Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex</brief_title>
  <official_title>Pilot Study of the in Vivo Efficacy of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if tobramycin inhalation powder (TIP) can reduce
      the amount of Burkholderia Cepacia Complex (BCC) species - type of bacteria, in the sputum of
      cystic fibrosis patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in sputum density of BCC in colony forming units (CFUs)/ml from day 0 to day 28 of TIP treatment.</measure>
    <time_frame>0 to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in pulmonary function tests, including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and maximal mid-expiratory flow rate (FEF25-75), measured at day 0 and day 28 of TIP treatment.</measure>
    <time_frame>0 to 28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in the measurement of markers of pulmonary inflammation (neutrophil counts, neutrophil elastase and IL-8 levels in sputum) measured at day 0 and day 28 of TIP treatment.</measure>
    <time_frame>0 to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Trough and peak sputum tobramycin concentration measured on day 28 of TIP treatment.</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in BCC planktonic and biofilm MICs to tobramycin measured on day 0 and on day 28 of TIP treatment.</measure>
    <time_frame>0 to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of adverse events measured at day 14 and at day 28 of TIP treatment.</measure>
    <time_frame>At Dat 0, Day 14, and Day 28</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Burkholderia Cepacia Infection</condition>
  <arm_group>
    <arm_group_label>TOBI Podhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOBI</intervention_name>
    <description>New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler</description>
    <arm_group_label>TOBI Podhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 years or older

          -  Diagnosis of CF based on the following: sweat chloride&gt;60 mEq/L or genotype with 2
             identifiable mutations consistent with CF; and one or more clinical features
             consistent with CF.

          -  Chronically infected with a Burkholderia cepacia complex species (&gt;50% of respiratory
             specimens positive in the 24 months prior to screening).

          -  Able to produce sputum (expectorated or induced).

          -  Able to reproducibly perform pulmonary function testing.

          -  Written informed consent provided.

        Exclusion Criteria:

          -  Post lung transplantation.

          -  Pregnancy.

          -  Acute exacerbation requiring IV or oral antibiotics within 14 days

          -  Patients currently receiving inhaled tobramycin/TOBI

          -  A septic or clinically unstable patient, as determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inhaled antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

